Premium
Treatment of nickel dermatitis with Antabuse® a double blind study
Author(s) -
Kaaber K.,
Menné T.,
Veien N.,
Hougaard P.
Publication year - 1983
Publication title -
contact dermatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.524
H-Index - 96
eISSN - 1600-0536
pISSN - 0105-1873
DOI - 10.1111/j.1600-0536.1983.tb04394.x
Subject(s) - medicine , placebo , erythema , double blind , dermatology , gastroenterology , surgery , alternative medicine , pathology
A double Wind, placebo‐controlled treatment with Antabuse® was carried out in 24 patients with hand eczema and nickel allergy. The amount of Antabuse® given was gradually increased from 50 to 200 mg daily. The maximum dose was given for ft weeks. During the treatment period, the dermatitis of 5 out of 11 patients in the group treated with Antabuse® healed, compared with 2 out of 13 in the group receiving the placebo. A statistical analysis was made of changes observed during the study, through the parameters: staling, frequency of flares, erythema, area involved and number of vesicles. Differences in results obtained with Antabuse® and the placebo were statistically significant only for the parameters scaling and frequency of flares ( p < 0.05). The difference between the sums of parameters following the 2 forms of treatment was not statistically significant ( p = 0.11). 2 patients treated with Antabuse® showed signs of hepatic toxicity; 1 of them had toxic hepatitis. No other significant side effects were seen.